Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Akebia Therapeutics (AKBA)

3.32   -0.05 (-1.48%) 03-05 09:18
Open: 3.35 Pre. Close: 3.37
High: 3.45 Low: 3.21
Volume: 6,964,608 Market Cap: 510M
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. The company's lead product candidate includes Auryxia, a ferric citrate to control the serum phosphorus levels in adult patients with chronic kidney disease (CKD), on dialysis (DD)-CKD, or the hyperphosphatemia indication (HIF); and vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to CKD in DD and non-dialysis patients. It has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of HIF-prolyl hydroxylases-targeted compounds worldwide. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 3.457 - 3.476 3.476 - 3.498
Low: 3.158 - 3.178 3.178 - 3.201
Close: 3.28 - 3.317 3.317 - 3.357

Technical analysis

as of: 2021-03-05 8:42:25 AM
Overall:       
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 5.12     One year: 6.00
Support: Support1: 3.17    Support2: 2.64
Resistance: Resistance1: 4.39    Resistance2: 5.14
Pivot: 4.04
Moving Average: MA(5): 3.41     MA(20): 4.18
MA(100): 3.26     MA(250): 6.67
MACD: MACD(12,26): -0.08     Signal(9): 0.08
Stochastic oscillator: %K(14,3): 9.63     %D(3): 10.25
RSI: RSI(14): 40.22
52-week: High: 13.71  Low: 2.09  Change(%): -63.4
Average Vol(K): 3-Month: 704753  10-Days: 731029

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
AKBA has closed above bottom band by 17.1%. Bollinger Bands are 83.7% wider than normal. The large width of the bands suggest high volatility as compared to AKBA's normal range. The bands have been in this wide range for 5 bars. This is a sign that the current trend might continue.

Headline News

Tue, 02 Mar 2021
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Tue, 02 Mar 2021
Akebia Therapeutics Inc (NASDAQ:AKBA) Reports A Drop Of 11.94% In 2020 Revenues: Appoints LeAnne M. Zumwalt To The Director Board - BP Journal

Mon, 01 Mar 2021
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Expected to Post Q1 2022 Earnings of ($0.26) Per Share - MarketBeat

Thu, 25 Feb 2021
Why Akebia Therapeutics Stock Is Plunging Today - Motley Fool

Thu, 25 Feb 2021
Premarket Mover: Akebia Therapeutics Inc (AKBA) Up 3.97% - InvestorsObserver

Thu, 25 Feb 2021
Akebia Therapeutics: 4Q Earnings Snapshot - San Francisco Chronicle

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Neutral Price to Earnings: Underperform
Return on Equity: Neutral Debt to Equity: Outperform
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 145
Shares Float (M) 136
% Held by Insiders 1.09
% Held by Institutions 78.78
Shares Short (K) 28,820
Shares Short P. Month (K) 23,730

Stock Financials

EPS -2.961
EPS Est This Year -2.640
EPS Est Next Year -1.720
Book Value (p.s.) 2.220
Profit Margin -126.86
Operating Margin -62.40
Return on Assets (ttm) -16.3
Return on Equity (ttm) -99.5
Qtrly Rev. Growth -34.8
Gross Profit (p.s.) 0.183
Sales Per Share 2.132
EBITDA (p.s.) -1.084
Qtrly Earnings Growth
Operating Cash Flow (M) -172
Levered Free Cash Flow (M) -77

Stock Valuations

PE Ratio -1.12
PEG Ratio
Price to Book value 1.50
Price to Sales 1.56
Price to Cash Flow -2.79

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.